Press Releases
Date
Article
12-17-2008
Supernus Pharmaceuticals Initiates Phase III Clinical Trial for Epliga™ in Refractory Partial Onset Epileptic Seizures
Once-Per-Day Therapy is Designed to Improve Patient Compliance and Reduce Adverse Events as Compared with Reference Product Trileptal®
04-23-2008
Supernus Pharmaceuticals Completes $75 Million Non-Recourse Note Offering Secured by Oracea® and Sanctura® XR Royalties
09-19-2007
Indevus Announces Allergan as New Partner for Sanctura® Brand
08-06-2007
Indevus Announces FDA Approval of Sanctura® XR
06-28-2006
Supernus Pharmaceuticals Announces Significant Progress with Partnership Products
Supernus Pharmaceuticals, Inc., announces that its partners CollaGenex and Indevus have recently achieved significant milestones in the development of their products that utilize Supernus’ technologies.
06-13-2006
Supernus Pharmaceuticals Announces Partnership with United Therapeutics
Supernus Pharmaceuticals, Inc. announces the signing of a definitive licensing agreement with United Therapeutics Corporation for the development of UT-15C, United Therapeutics’ oral prostacyclin analog.
02-21-2006
SUPERNUS PHARMACEUTICALS ANNOUNCES SECOND CLOSING RAISING AN ADDITIONAL $17.5 MILLION
Supernus Pharmaceuticals, Inc., announces the closing of a second round of financing raising an additional $17.5 million.
01-12-2006
Supernus Pharmaceuticals Acquires Drug Formulation Business Of Shire Laboratories Inc.
Supernus Pharmaceuticals, Inc., a newly formed specialty pharmaceuticals company, announces the acquisition of substantially all the assets comprising the product formulation and development business of Shire Laboratories Inc. a subsidiary of Shire plc.
View Archived Press Releases
